Replies to post #86839 on Biotech Values

[DewDiligence]

Late-Stage Products Looking for a Home

Criteria for inclusion:
a) Program has completed phase-2b or beyond and is non-partnered; AND
b) Company lacks the financial resources to commercialize the product on its own.

Edits: Changed the first criterion above to include cases where the drug
has completed phase-2b but is not yet in phase-3 (e.g. TRGT’s TC-5214).

 
 Company  Product    Phase/status  Indication (notes) 
 =======  =======    ============  ================== 
 ARNA     Lorcaserin      3        Obesity     
 BPAX     Libigel         3        Female Sexual Desire Disorder   
 GNVC     TNFerade        3        Non-met pancreatic cancer     
 JAV      Dyloject        3        Post-op pain (approved in UK)   
 JAV      Ketamine        3        Acute pain   
 OREX     Contrave        3        Obesity     
 OXGN     Zybrestat       3        Anaplastic thyroid cancer        
 MNKD     Afresa       pre-BLA     Type-1/2 diabetes   
 Pharming Rhucin       pre-BLA     HAE (rejected and resubmitted in EU)    
 SVNT     Krystexxa    CRL rec’d   Gout (CMC section of BLA has problems)  
 VVUS     Qnexa        pre-NDA     Obesity 

Procedure for Updating Table

1. Copy the text in this post into a word processor.

2. Using a monospace font (e.g. Courier) to facilitate tabular
alignment, make your additions and modifications, inserting
them in the table in alphabetical order. NOTE: use spaces
rather than tab characters.

3. Add a brief note in the “Edits:” line atop the table to
describe your changes.

4. Insert the iHub formatting directives: Put [ pre ] at the
beginning of the table without the surrounding spaces, and
put [ /pre ] at the end of the table without the surrounding
spaces.

5. Post your text as a reply to this message.

Thank you for your cooperation.